BioSpace News Archive

The MemorialCare Joint Replacement Center at Long Beach Medical Center is the first hospital in Los Angeles County to use new technology to offer guided personalized surgery for shoulder replacements.

Partnership to provide B2B ground transportation solutions for customers in need of non-medical travel assistance from transportation hubs across the world

Agendia, Inc., a world leader in precision oncology, announced today that its MammaPrint Breast Cancer Risk-of-Recurrence Test is the only molecular diagnostic indicated for use with patients who have breast cancer that has spread to their lymph nodes according to the updated Cancer Care Ontario Guidelines.

RevoluGen, a privately held scientific company specialising in the development and commercialisation of nucleic acid isolation and purification products, today announces the appointment of Stefano Giolito as Chief Marketing Officer, effective immediately.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Victor Paulus, Ph.D. as Senior Vice President, Regulatory Affairs.

Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an R&D collaboration and Option & Licence Agreement to research and develop gene therapy products for the treatment of an inherited retinal disease

Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces interim results from the Phase II INFORAAA study, which examined the effect of Traumakine on mortality (predominantly for Multi-Organ Failure, MOF) and pharmacodynamic biomarkers of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.

PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today that it has completed $50 million in new financing with Perceptive Advisors.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will mark their 25th anniversary tomorrow with the start of their Annual Conference, this year in Orlando, Florida.

Headlines about cancer care refer to a revolution—one-time treatments bring patients who had lost hope back from the brink, and some go on to live long, meaningful lives.